The current results indicated that, in transplantation-eligible patients who receive IMiDs as initial therapy followed by early stem cell mobilization, delayed SCT results in similar overall survival compared with early SCT. It is noteworthy that an excellent 4-year survival rate of >80% was observed among transplantation-eligible patients who received initial therapy with LD regardless of the timing of transplantation.
Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. kumar.shaji [at] mayo.edu
Cancer. 2012 Mar;118(6):1585-92
© Galenicom 1999-2013